Despite reporting consistent quarter-on-quarter growth, India’s Indoco Remedies Limited is yet to see an expected revival in its domestic business. After its sales in India took a hit over the past year due to COVID-19, the company had predicted growth based on “the bounce back of the Indian pharma market.”
However, commenting on the firm’s third-quarter results, Indoco’s managing director Aditi Panandikar said “While the revenue from International business has...







